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Dear editor
We read with interest the article entitled “Effects of tafluprost treatment for 3 years 
in patients with normal-tension glaucoma” by Inoue et al.1 In this study, the authors 
reported the efficacy of tafluprost in naïve patients with normal-tension glaucoma 
(NTG) over 3 years of follow-up. 
The intraocular pressure (IOP)-lowering efficacy of tafluprost in NTG has been 
recently reported by Mizoguchi et al2 and Nakano et al.3 
Whereas tafluprost is available in Europe in a preservative-free formulation, the 
three aforementioned studies1–3 were all carried out in Japan, where tafluprost is on 
the market as a benzalkonium chloride (BAK)-containing formulation. 
Recent literature reported BAK-related ocular surface inflammation and epithelial 
damage,4 which led to the development of preservative-free antiglaucoma drugs. The 
cytotoxic effect of BAK on conjunctival and corneal epithelium has been claimed to 
increase ocular penetration of topical drug, enhancing the therapeutic effect.5 
As the presence of preservative may play a role in the IOP-lowering effect, we 
believe it is of interest to report the efficacy of BAK-free formulations in NTG. 
In a previous study by our group, BAK-free tafluprost showed a comparable efficacy 
to other prostaglandin analogs, with a safe profile in patients with primary open-angle 
glaucoma.6 In this letter, we want to report our experience with preservative-free taflu-
prost in patients with NTG. Herein, we present a retrospective study on 58 eyes of 
58 patients (mean age 65.8±9.2 years, range 43–91 years) with NTG previously treated 
with BAK-preserved latanoprost who were switched to unpreserved tafluprost for ocu-
lar surface discomfort. The study was carried out with approval from the Institutional 
Ethics Committee (San Giuseppe Hospital, MultiMedica) and adhered to the tenets 
of the Declaration of Helsinki. 
To be included, patients had to have unilateral or bilateral NTG. Diagnosis of NTG 
was made on the basis of optic-disk abnormalities and visual-field defects judged by 
a trained glaucoma specialist to be characteristic of glaucoma with IOP 21 mmHg 
at any time points of the diurnal IOP curve (8 am, 11 am, 2 pm, 5 pm). 
All patients were followed in our hospital (San Giuseppe Hospital) from Janu-
ary 2011 to December 2013. Inclusion criteria were: at least 3 months of treatment 
with BAK-preserved latanoprost followed by at least 3 months of treatment with 
unpreserved tafluprost; switch to tafluprost due to ocular discomfort; and availability 
of data from three diurnal IOP curves (untreated, treated with latanoprost, and after 
switch to tafluprost). 
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Both latanoprost and tafluprost significantly reduced the 
diurnal mean IOP compared to baseline (12.7±1.7 mmHg ver-
sus 14.9±1.9 mmHg, –15%, P0.001 and 12.2±1.8 mmHg 
versus 14.9±1.9 mmHg, –18%, P0.001,  respectively) 
(Figure 1). Conjunctival hyperemia was reported in 17% and 
8% of patients and fluorescein corneal staining in 6% and 
2% of patients receiving latanoprost and tafluprost, 
respectively. 
The retrospective nature of this study, the absence of a 
wash-out period, and the short follow-up are all limitations 
of this report and we are aware that our results need to be 
confirmed by powered, prospective, randomized clinical tri-
als. However, to the best of our knowledge, this is the first 
report on the efficacy of BAK-free tafluprost in NTG.
In our study, the percentage IOP reduction from untreated 
baseline for both latanoprost (15%) and tafluprost (18%) 
was similar to that reported in other studies investigating 
the efficacy of prostaglandin analogs in NTG and ranging 
from 16%7 to 19%.8
This study suggests the effectiveness of preservative-
free tafluprost in NTG, showing results comparable to those 
obtained in Japanese patients1–3 using a BAK-preserved 
formulation. 
Disclosure
The authors report no conflicts of interest in this work.
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Figure 1 Intraocular pressure at baseline, with latanoprost, and after switch from 
latanoprost to tafluprost.
Notes: Data are shown as mean ± standard deviation. *P<0.001, compared to 
baseline; **P=0.008, compared to latanoprost.
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Dear editor
The authors would like to thank you for reviewing the present 
manuscript and for reading our previous paper on the effects 
of tafluprost in glaucoma patients.1 We would like to thank 
Dr M Sacchi for the valuable comments. 
In patients with normal-tension glaucoma, the efficacy in 
decreasing intraocular pressure (IOP) and reducing corneal 
staining was preserved following a change in treatment 
from latanoprost with preservatives to tafluprost without 
preservatives. However, it remains unknown whether the 
concordance of the results obtained from the two different 
treatments was due to the change in the main agent (from 
latanoprost to tafluprost) and/or to the change in the use of 
preservatives in the eyedrops. Furthermore, discomfort was 
reported in patients enrolled in the treatment group, where 
latanoprost with preservatives was used. Therefore, we sug-
gest that the increased adherence to the treatment was due 
to the use of eyedrops containing tafluprost without preser-
vatives. Our opinions about products without preservatives 
are stated below.
The risks associated with the use of preservatives, par-
ticularly benzalkonium hydrochloride (BAC), include the 
appearance of adverse reactions such as hyperemia, allergy, 
and corneal epithelium disorder.2–4 These adverse reactions 
can contribute to a decrease in adherence to the treatment 
and a reduction in the efficacy of reducing IOP. A benefit 
of preservative use is the occurrence of a comfortable tran-
sition of eye drops to the intracameral increased. A more 
 suitable study would compare the effects of medicated eye-
drops with and without preservatives; however, tafluprost 
without preservatives was not available for patient treatment 
in Japan during the establishment of the study.1 Unit doses of 
tafluprost without preservatives became available in Japan 
in October 2013; therefore, we aim to subsequently compare 
the effects of tafluprost, both with and without preservatives, 
in a future study.
Latanoprost without preservatives (with formulation by 
filtration) has been available in Japan since 2010. We previ-
ously studied the effects of using latanoprost both with and 
without preservatives.5 Because this study was published in 
a Japanese journal, the results are currently only available 
in Japanese.
In our previous manuscript,5 three treatments were inves-
tigated: latanoprost with BAC was changed to latanoprost 
without BAC; latanoprost without BAC; and latanoprost 
without BAC was added to carteolol without BAC; each 
of the treatments were administered to NTG patients. The 
conclusion from the study was that IOP was maintained 
and adverse reactions of superficial punctate keratitis were 
 weakened following 3 months of treatment in all cases in 
which latanoprost with BAC was previously used. 
A translated version of the abstract from the Japanese 
manuscript is shown below.
Purpose: To investigate the ocular hypotensive effects and 
safety of latanoprost without benzalkonium hydrochloride 
(BAC).
Methods: Twenty patients with normal-tension glau-
coma (monotherapy group), 14 patients who changed 
from latanoprost with BAC (changed therapy group), 
and 10 patients receiving added carteolol without BAC 
(additional therapy group). Intraocular pressure (IOP) 
and adverse reactions were checked at 1 and 3 months 
after treatment. In the changed-therapy group, superficial 
punctate keratitis was checked and compared before and 
after treatment.
Results: After 1 and 3 months, intraocular pressure 
decreased significantly in the mono and additional therapy 
groups, but after 3 months it remained unchanged in  
the changed therapy group. Because of adverse  reactions, 
2 patients (4.5%) discontinued latanoprost without 
BAC. After 1 month, superficial punctate keratitis had  
improved in 6 patients (42.9%) in the changed therapy 
group.
Conclusion: Latanoprost without BAC had strong 
hypotensive effects and was safely used in 95% of cases.5
In conclusion, eyedrops without preservatives are associ-
ated with a decrease in adverse reactions and improved adher-
ence to the treatment. As such, we hope that the prescription 
and usage rates for these types of eyedrops increase in future 
clinical practice.
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